Table 1.
Baseline Patient Characteristics
| TTFields-treated Patients, N (%) | Control Patients, N (%) | |
|---|---|---|
| Patient, N | 55 | 57 |
| Gender | ||
| Female | 17 (31%) | 23 (40%) |
| Male | 38 (69%) | 34 (60%) |
| Age | ||
| Median age | 59 | 58 |
| Age range | 26-79 | 17-75 |
| Histology | All glioblastoma | All glioblastoma |
| Tumor grade | All IV | All IV |
| Primary tumor location | ||
| Temporal lobe | 16 (29%) | 10 (18%) |
| Frontal lobe | 14 (25%) | 17 (30%) |
| Parietal lobe | 9 (16%) | 12 (21%) |
| Brain, NOS | 12 (22%) | 17 (30%) |
| Cerebellum | 1 (2%) | 0 |
| Occipital lobe | 2 (4%) | 0 |
| Thalamus | 1 (2%) | 1 (2%) |
| IDH1/2 mutation % (N) | 5 (9%) | 3 (5%) |
| MGMT methylation % (N) | 24/53 (45%) | 26/56 (46%) |
Abbreviations: IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine-DNA methyltransferase; NOS, not otherwise specified; TTFields, Tumor-Treating Fields